Anastasios Bonakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasios Bonakis has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Georgios Tsivgoulis
Second Department of Neurology, National and Kapodistrian University of Athens, Attikon University Hospital, Greece (G.T.).
15 shared publications - Georgios P. Paraskevas
Neurochemistry and Biological Markers Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, Vass. Sophias Ave. 74, 11528 Athens, Greece
10 shared publications - Ioanna Tsantzali
2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
8 shared publications - Panagiota-Eleni Tsalouchidou
Second Department of Neurology Attikon University Hospital, National and Kapodistrian University of Athens Athens Greece
8 shared publications - Sotirios Giannopoulos
Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
8 shared publications - Aikaterini Theodorou
Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece
6 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1744
Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence
Background: Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations. Objective: We aim to review BRV use beyond approved indications and in special populations. Methods: MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling. Results: The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited. Conclusions: BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.
- 3 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1744
Open AccessBrivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence
Background: Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations. Objective: We aim to review BRV use beyond approved indications and in special populations. Methods: MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling. Results: The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited. Conclusions: BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.
- Open Access
- 5 October 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 186
What shapes health-related quality of life in drug-resistant epilepsy? Clinical, emotional, and cognitive predictors
- 5 October 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 186
Open AccessWhat shapes health-related quality of life in drug-resistant epilepsy? Clinical, emotional, and cognitive predictors
- Open Access
- 27 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Psychological resilience as a key pathway between depression and executive functioning in epilepsy
- 27 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Open AccessPsychological resilience as a key pathway between depression and executive functioning in epilepsy
- Open Access
- 16 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Resilience as a mediating mechanism between psychological distress and quality of life in epilepsy
- 16 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Open AccessResilience as a mediating mechanism between psychological distress and quality of life in epilepsy
- Open Access
- 7 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1426-1436
Neuroimaging of the ictal–interictal continuum: Where do we stand? A systematic review and meta‐analysis of current evidence
Objective: Patterns within the ictal–interictal continuum (IIC) are frequently encountered in critically ill patients undergoing continuous electroencephalographic studies and may reflect ongoing ictal activity or secondary brain injury. Peri‐ictal neuroimaging abnormalities (PNA) have been described in association with status epilepticus (SE), but their occurrence in patients with IIC across different neuroimaging modalities remains incompletely characterized. We aimed to assess the occurrence of PNA in adults with IIC across structural and functional neuroimaging techniques. Methods: We performed a systematic review and meta‐analysis following PRISMA 2020 guidelines. PubMed, Embase, and Scopus were searched up to January 2026 for studies reporting PNA in adults with IIC. Eligible modalities included magnetic resonance imaging (MRI), CT perfusion (CTP), and positron emission tomography (PET). Pooled detection rates were estimated using random‐effects generalized linear mixed models. Results: Of 8400 records identified, seven studies met the inclusion criteria. Of these, four contributed MRI data (98 patients), two—CTP data (38 patients), and two—PET data (30 patients); no SPECT study was identified. One study contributed data to two modalities. Pooled proportion of PNA was 0.41 (95% CI: 0.30–0.52; I 2 = 30.4%) for MRI, 0.34 (95% CI: 0.21–0.50; I 2 = 0%) for CTP, and 0.90 (95% CI: 0.73–0.97; I 2 = 0%) for PET. Significance: There are currently a limited number of studies evaluating PNA in IIC. PET showed the highest pooled proportion of PNA, although these findings should be interpreted cautiously. Further studies are required to better define the neuroimaging spectrum within the IIC and to clarify its clinical and diagnostic implications.
- 7 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1426-1436
Open AccessNeuroimaging of the ictal–interictal continuum: Where do we stand? A systematic review and meta‐analysis of current evidence
Objective: Patterns within the ictal–interictal continuum (IIC) are frequently encountered in critically ill patients undergoing continuous electroencephalographic studies and may reflect ongoing ictal activity or secondary brain injury. Peri‐ictal neuroimaging abnormalities (PNA) have been described in association with status epilepticus (SE), but their occurrence in patients with IIC across different neuroimaging modalities remains incompletely characterized. We aimed to assess the occurrence of PNA in adults with IIC across structural and functional neuroimaging techniques. Methods: We performed a systematic review and meta‐analysis following PRISMA 2020 guidelines. PubMed, Embase, and Scopus were searched up to January 2026 for studies reporting PNA in adults with IIC. Eligible modalities included magnetic resonance imaging (MRI), CT perfusion (CTP), and positron emission tomography (PET). Pooled detection rates were estimated using random‐effects generalized linear mixed models. Results: Of 8400 records identified, seven studies met the inclusion criteria. Of these, four contributed MRI data (98 patients), two—CTP data (38 patients), and two—PET data (30 patients); no SPECT study was identified. One study contributed data to two modalities. Pooled proportion of PNA was 0.41 (95% CI: 0.30–0.52; I 2 = 30.4%) for MRI, 0.34 (95% CI: 0.21–0.50; I 2 = 0%) for CTP, and 0.90 (95% CI: 0.73–0.97; I 2 = 0%) for PET. Significance: There are currently a limited number of studies evaluating PNA in IIC. PET showed the highest pooled proportion of PNA, although these findings should be interpreted cautiously. Further studies are required to better define the neuroimaging spectrum within the IIC and to clarify its clinical and diagnostic implications.
- 21 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 184
Alexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy
- 21 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 184
Alexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy
- Open Access
- 29 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9531
The Biomarker Profile of Alzheimer’s Disease for Disease-Modifying Treatment Eligibility: Questions and Debates
Alzheimer’s disease (AD) is the most common cause of cognitive decline; currently, anti-amyloid monoclonal antibodies are available for clinical use as disease-modifying treatments, while many other substances are being tested in clinical trials. Molecular biomarkers for AD have been studied for more than two decades, and various guidelines and diagnostic recommendations have been published. However, there are still questions and controversies about the biomarker profile needed to confirm AD and the eligibility for such established treatments and clinical trials. Is amyloid positivity sufficient for eligibility, or is a biomarker for tau biochemistry/pathology also needed? What is the role of hybrid ratios combining amyloid and tau? Should we rely on plasma biomarkers alone? This review aimed to describe and discuss such questions and controversies.
- 29 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9531
Open AccessThe Biomarker Profile of Alzheimer’s Disease for Disease-Modifying Treatment Eligibility: Questions and Debates
Alzheimer’s disease (AD) is the most common cause of cognitive decline; currently, anti-amyloid monoclonal antibodies are available for clinical use as disease-modifying treatments, while many other substances are being tested in clinical trials. Molecular biomarkers for AD have been studied for more than two decades, and various guidelines and diagnostic recommendations have been published. However, there are still questions and controversies about the biomarker profile needed to confirm AD and the eligibility for such established treatments and clinical trials. Is amyloid positivity sufficient for eligibility, or is a biomarker for tau biochemistry/pathology also needed? What is the role of hybrid ratios combining amyloid and tau? Should we rely on plasma biomarkers alone? This review aimed to describe and discuss such questions and controversies.
- Open Access
- 1 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7410
APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population
Alzheimer’s disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E (APOE) is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the most common genotype is the ε3/ε3. Recently, it has been observed that subjects with the ε4/ε4 genotype may show near-full penetrance of AD biology (pathology and biomarkers), leading to the suggestion that ε4 homozygosity may represent a distinct genetic type of AD. The aim of the present study was to investigate the role of ε4 homozygosity or heterozygosity in the presence or absence of the AD biomarker profile in patients with cognitive disorders in the Greek population. A total of 274 patients were included in the study. They underwent APOE genotyping and cerebrospinal fluid (CSF) biomarker profiling. The presence of ε4 was associated with a lower age of symptom onset and decreased amyloid biomarkers (irrespective to AD or non-AD profiles), and predicted the presence of an AD profile by a positive predictive value approaching 100%. In conclusion, the ε4 allele has a significant effect on the risk and clinical parameters of cognitive impairment and AD in the Greek population, while the ε4/ε4 genotype may be highly indicative of the (co)existence of AD in cognitively impaired patients.
- 1 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7410
Open AccessAPOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population
Alzheimer’s disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E (APOE) is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the most common genotype is the ε3/ε3. Recently, it has been observed that subjects with the ε4/ε4 genotype may show near-full penetrance of AD biology (pathology and biomarkers), leading to the suggestion that ε4 homozygosity may represent a distinct genetic type of AD. The aim of the present study was to investigate the role of ε4 homozygosity or heterozygosity in the presence or absence of the AD biomarker profile in patients with cognitive disorders in the Greek population. A total of 274 patients were included in the study. They underwent APOE genotyping and cerebrospinal fluid (CSF) biomarker profiling. The presence of ε4 was associated with a lower age of symptom onset and decreased amyloid biomarkers (irrespective to AD or non-AD profiles), and predicted the presence of an AD profile by a positive predictive value approaching 100%. In conclusion, the ε4 allele has a significant effect on the risk and clinical parameters of cognitive impairment and AD in the Greek population, while the ε4/ε4 genotype may be highly indicative of the (co)existence of AD in cognitively impaired patients.
- Open Access
- 20 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2904
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer’s Disease
Background: Alzheimer’s disease (AD) may present with pure (typical or atypical) and mixed phenotypes, sometimes causing difficulties in (differential) diagnosis. In order to achieve a diagnostic accuracy as high as possible, the diagnosis of AD during life depends on various biomarkers, including the cerebrospinal fluid (CSF) biomarkers. Methods: Classical CSF AD biomarkers were determined in a total of 61 patients, classified as both beta amyloid- and tau-positive A+T+ (or A+T1+ according to the recently revised Alzheimer Association criteria for diagnosis and staging of AD). Twenty one of these patients fulfilled the criteria for mixed AD (mixed with Lewy bodies, cerebrovascular disease, or normal pressure hydrocephalus), whilst 40 had pure AD. Results: Patients did not differ with respect to gender, education, disease duration, and cognitive status. After controlling for confounding factors, no difference was observed between mixed and pure AD groups in Aβ42 or Aβ42/Aβ40 levels. Although by definition, patients of both groups had abnormal (increased) levels of phospho-tau181, the mixed AD group presented with lower (less abnormal) levels of phospho-tau181 and total tau as compared to the pure group. Conclusions: In patients with AD of comparable cognitive status, mixed AD cases may present with lower levels of tau proteins and, if close to the cut-off values, diagnostic uncertainty may be increased.
- 20 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2904
Open AccessCerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer’s Disease
Background: Alzheimer’s disease (AD) may present with pure (typical or atypical) and mixed phenotypes, sometimes causing difficulties in (differential) diagnosis. In order to achieve a diagnostic accuracy as high as possible, the diagnosis of AD during life depends on various biomarkers, including the cerebrospinal fluid (CSF) biomarkers. Methods: Classical CSF AD biomarkers were determined in a total of 61 patients, classified as both beta amyloid- and tau-positive A+T+ (or A+T1+ according to the recently revised Alzheimer Association criteria for diagnosis and staging of AD). Twenty one of these patients fulfilled the criteria for mixed AD (mixed with Lewy bodies, cerebrovascular disease, or normal pressure hydrocephalus), whilst 40 had pure AD. Results: Patients did not differ with respect to gender, education, disease duration, and cognitive status. After controlling for confounding factors, no difference was observed between mixed and pure AD groups in Aβ42 or Aβ42/Aβ40 levels. Although by definition, patients of both groups had abnormal (increased) levels of phospho-tau181, the mixed AD group presented with lower (less abnormal) levels of phospho-tau181 and total tau as compared to the pure group. Conclusions: In patients with AD of comparable cognitive status, mixed AD cases may present with lower levels of tau proteins and, if close to the cut-off values, diagnostic uncertainty may be increased.